Skip to content

Medical emergency? What to do

Psoriasis drug shown highly effective in trial

3-RXPublished October 4, 20072 min read

Key points

  • Johnson & Johnson's experimental treatment for psoriasis proved safe and highly effective in a late-stage trial, positioning it as a potential strong rival to current medicines, the company said on Wednesday.
  • Patients were divided into groups that received either a placebo, two 45-milligram doses of the medicine given four weeks apart, or two 90-milligram doses, also four weeks apart.
  • About 42 percent of patients taking the lower doses and 51 percent of those in the high-dose group reported a 90 percent reduction in symptoms after 12 weeks -- "nearly complete clearance of psoriasis" -- J&J said.
  • "The most common (side effects) were a little sore throat and runny nose, or a bit of headache, but they weren't common," Dr.

Johnson & Johnson's experimental treatment for psoriasis proved safe and highly effective in a late-stage trial, positioning it as a potential strong rival to current medicines, the company said on Wednesday.

More than two-thirds of patients with moderate to severe forms of the inflammatory skin condition achieved at least a 75 percent reduction in symptoms after 12 weeks of treatment with the injectable medicine CNTO 1275 (ustekinumab), J&J said.

Patients were divided into groups that received either a placebo, two 45-milligram doses of the medicine given four weeks apart, or two 90-milligram doses, also four weeks apart.

J&J said 67 percent of patients receiving the lower doses achieved at least 75 percent reduction in symptoms, such as red scaly patches, compared with 76 percent of those taking the higher dosages and 4 percent in the placebo group.

About 42 percent of patients taking the lower doses and 51 percent of those in the high-dose group reported a 90 percent reduction in symptoms after 12 weeks -- "nearly complete clearance of psoriasis" -- J&J said. That compared with 1 percent in the placebo group.

A substantial number of patients who received another dose of CNTO 1275 at 16 weeks maintained symptom control for an additional three months, the company said.

"The most common (side effects) were a little sore throat and runny nose, or a bit of headache, but they weren't common," Dr. Craig Leonardi, a St. Louis University Medical School dermatologist who led the study, said in a telephone interview.

"This looks to have one of the cleanest side-effect profiles we've seen for any biologic drugs to date" used to treat psoriasis, Leonardi said.

Results of the Phase III trial, which involved more than 1,200 patients, were presented at the World Congress of Dermatology in Buenos Aires.

Abbott Laboratories Inc. on Monday reported similarly favorable results for its rival experimental psoriasis drug, ABT-874, in a mid-stage trial.

The J&J and Abbott medicines work by blocking interleukin-12 and interleukin-23 - two proteins linked to inflammation in psoriasis and other autoimmune disorders.

Two leading approved psoriasis drugs, Amgen Inc's Enbrel and J&J's Remicade, work by blocking another inflammation-causing protein, called tumor necrosis factor (TNF).

Abbott's Humira, a blockbuster treatment for rheumatoid arthritis that is awaiting U.S. approval for use in treating psoriasis, also blocks TNF.

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

Keep reading

Cancer

Avastin Slows Resistant Ovarian Cancer

Progression of platinum-resistant ovarian cancer slowed by more than 50% in patients who received bevacizumab (Avastin) plus chemotherapy compared with nonplatinum chemotherapy alone, results of a randomized trial…

3 min read

Drug News

Prevnar trial results needed for CDC recommendation

Advisors to the U.S. Centers for Disease Control and Prevention on Wednesday will wait for results from a trial of Pfizer Inc's Prevnar 13 pneumonia vaccine before deciding whether to recommend its use in all adults…

1 min read

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.